Teva Pharmaceuticals

Teva Pharmaceuticals's reported carbon emissions

Teva Pharmaceuticals, headquartered in Israel, has set ambitious targets for reducing its greenhouse gas (GHG) emissions. The company aims to achieve net-zero emissions across its operations and value chain by 2045. For near-term reductions, Teva has committed to lowering absolute Scope 1 and 2 GHG emissions by 25% by 2025 and by 46% by 2030, using 2019 as the baseline year. Additionally, Teva is targeting a 25% reduction in absolute Scope 3 GHG emissions by 2030, with 2020 as the baseline. These targets are aligned with a 1.5°C warming scenario. In terms of reported emissions, for the year 2025, Teva reported a total of approximately 301.8 million kg CO2e for Scope 1 and Scope 2 emissions (using market-based reporting). Scope 3 emissions for 2025 were substantial, with purchased goods and services accounting for approximately 2.17 billion kg CO2e, followed by the use of sold products at about 715.3 million kg CO2e, and the end-of-life treatment of sold products at approximately 427.8 million kg CO2e. For 2024, Teva reported Scope 1 and 2 emissions of approximately 449.1 million kg CO2e (market-based). Scope 3 emissions in 2024 were primarily driven by purchased goods and services at around 2.46 billion kg CO2e and the use of sold products at approximately 723.8 million kg CO2e. In 2023, Teva's Scope 1 and 2 emissions were approximately 468.9 million kg CO2e (market-based). Scope 3 emissions for 2023 included about 2.64 billion kg CO2e from purchased goods and services and approximately 658.0 million kg CO2e from the use of sold products. Teva's emissions data is not cascaded from a parent organisation.